Colonic Neoplasms News - LARVOL Sigma

Colonic Neoplasms

Welcome, Profile Billing Logout

81 Mechanisms of Action

«1 2 3 4 5 6 7 8 9 10 111213 »

|||||||||| Trial completion: The Effect of Case Management in Complex Cancer Pathways (clinicaltrials.gov) - Aug 29, 2012
P=N/A, N=280, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed

|||||||||| Trial completion: Improving Bowel Preparation for Colonoscopy With a Simple Educational Card (clinicaltrials.gov) - Aug 28, 2012
P=N/A, N=2000, Completed, Sponsor: Boston Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  dasatinib / Generic mfg.
Enrollment closed, Metastases:  Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) -  Aug 23, 2012
P2, N=19, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Active, not recruiting

||||||||||  5-fluorouracil / Generic mfg.
Biomarker, Enrollment closed, Surgery:  Study of Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery and Chemotherapy (clinicaltrials.gov) -  Aug 21, 2012
P=N/A, N=3000, Active, not recruiting,  Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Completed --> Active, not recruiting Recruiting --> Active, not recruiting

|||||||||| Enrollment change: Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement (clinicaltrials.gov) - Aug 14, 2012
P2, N=2260, Completed, Sponsor: Group Health Cooperative
Recruiting --> Active, not recruiting N=1800 --> 2260

|||||||||| Trial completion: Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement (clinicaltrials.gov) - Aug 14, 2012
P2, N=2260, Completed, Sponsor: Group Health Cooperative
N=1800 --> 2260 Active, not recruiting --> Completed

||||||||||  JI-101 / Jubilant Pharmova
Trial termination, Metastases:  Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers (clinicaltrials.gov) -  Aug 12, 2012
P1/2, N=19, Terminated,  Sponsor: University of Utah
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Lack of drug efficacy

||||||||||  JI-101 / Jubilant Pharmova
Enrollment change, Metastases:  Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers (clinicaltrials.gov) -  Aug 12, 2012
P1/2, N=19, Terminated,  Sponsor: University of Utah
Active, not recruiting --> Terminated; Lack of drug efficacy N=40 --> 19

|||||||||| Trial completion: Neurological Effects of Chemotherapy and Radiation Therapy in Patients With Colon Cancer (clinicaltrials.gov) - Aug 12, 2012
P=N/A, N=42, Completed, Sponsor: University of Arizona
N=40 --> 19 Recruiting --> Completed

||||||||||  Vectibix (panitumumab) / Amgen
Trial termination:  Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors (clinicaltrials.gov) -  Aug 6, 2012
P=N/A, N=10, Terminated,  Sponsor: Stanford University
Recruiting --> Completed Recruiting --> Terminated; Low Accrual

||||||||||  Erbitux (cetuximab) / Eli Lilly
Trial termination, Surgery:  Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery (clinicaltrials.gov) -  Aug 6, 2012
P=N/A, N=9, Terminated,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated; Low Accrual Recruiting --> Terminated

||||||||||  Vectibix (panitumumab) / Amgen
Enrollment change:  Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors (clinicaltrials.gov) -  Aug 6, 2012
P=N/A, N=10, Terminated,  Sponsor: Stanford University
Recruiting --> Terminated N=400 --> 10

||||||||||  Erbitux (cetuximab) / Eli Lilly
Enrollment change, Surgery:  Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery (clinicaltrials.gov) -  Aug 6, 2012
P=N/A, N=9, Terminated,  Sponsor: National Cancer Institute (NCI)
N=400 --> 10 N=12 --> 9

|||||||||| Trial completion, Surgery: Rehabilitation Following Laparoscopic Colonic Surgery (clinicaltrials.gov) - Aug 6, 2012
P=N/A, N=50, Completed, Sponsor: Aarhus University Hospital
N=12 --> 9 Recruiting --> Completed

||||||||||  Recentin (cediranib) / AstraZeneca, RG4733 / Roche
Enrollment closed, Metastases:  Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Aug 2, 2012
P1, N=50, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  AVX-701 / AlphaVax
Enrollment change, Metastases:  CEA(6D)VRP: A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies (clinicaltrials.gov) -  Jul 10, 2012
P1/2, N=28, Completed,  Sponsor: AlphaVax, Inc.
Recruiting --> Active, not recruiting N=36 --> 28

||||||||||  AVX-701 / AlphaVax
Trial completion, Metastases:  CEA(6D)VRP: A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies (clinicaltrials.gov) -  Jul 10, 2012
P1/2, N=28, Completed,  Sponsor: AlphaVax, Inc.
N=36 --> 28 Active, not recruiting --> Completed

||||||||||  Erbitux (cetuximab) / Eli Lilly
New P1 trial, Metastases:  Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer (clinicaltrials.gov) -  Jul 9, 2012
P1, N=12, Completed,  Sponsor: Fox Chase Cancer Center

|||||||||| Enrollment open: Molecular Genetic and Pathological Studies of Anal Tumors (clinicaltrials.gov) - Jul 4, 2012
P=N/A, N=300, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| Trial completion, Metastases: Gene Expression Profiling in Normal Tissue and Tumor Tissue From Patients With Colon Cancer That Has Spread to the Liver, Lungs, or Peritoneum (clinicaltrials.gov) - Jun 26, 2012
P=N/A, N=10, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

|||||||||| Trial completion, Adherence: Adherence and the Economics of Colon Cancer Screening (clinicaltrials.gov) - Jun 10, 2012
P=N/A, N=1000, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment change: Patient Navigator Project (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=1267, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed N=694 --> 1267

|||||||||| New P2 trial: Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer (clinicaltrials.gov) - May 23, 2012
P2, N=120, Recruiting, Sponsor: Mayo Clinic

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy, Metastases:  Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors (clinicaltrials.gov) -  Apr 24, 2012
P1, N=54, Completed,  Sponsor: National Cancer Institute (NCI)
N=694 --> 1267 Active, not recruiting --> Completed

|||||||||| MSi-H Biomarker: Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting (clinicaltrials.gov) - Apr 19, 2012
P=N/A, N=1200, Enrolling by invitation, Sponsor: Kaiser Permanente

|||||||||| Enrollment closed, HEOR, Surgery, Cost effectiveness: ONKOLINK: Follow-up After Surgery for Colon Cancer. General Practice vs. Surgical-based Follow-up? (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=180, Active, not recruiting, Sponsor: University Hospital of North Norway
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

|||||||||| Trial completion: Aerobic Capacity and Body Composition in Colon Cancer Patients (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=40, Completed, Sponsor: AHS Cancer Control Alberta
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Combination therapy, Metastases:  Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment (clinicaltrials.gov) -  Mar 26, 2012
P2, N=58, Completed,  Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed N=86 --> 58

|||||||||| New P2 trial: Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis (clinicaltrials.gov) - Mar 26, 2012
P2, N=30, Recruiting, Sponsor: Gachon University Gil Medical Center

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy, Metastases:  Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment (clinicaltrials.gov) -  Mar 26, 2012
P2, N=58, Completed,  Sponsor: Roswell Park Cancer Institute
N=86 --> 58 Active, not recruiting --> Completed

|||||||||| New P1 trial: PILLAR II: Perfusion Assessment in Laparoscopic Left Anterior Resection (clinicaltrials.gov) - Mar 20, 2012
P1, N=150, Active, not recruiting, Sponsor: Novadaq Technologies Inc.

||||||||||  melphalan / Generic mfg.
Trial completion, Metastases:  Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver (clinicaltrials.gov) -  Mar 20, 2012
P2, N=0, Completed,  Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Avastin (bevacizumab) / Roche
Enrollment change:  Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) (clinicaltrials.gov) -  Mar 8, 2012
P2, N=65, Terminated,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed N=93 --> 65

||||||||||  Erbitux (cetuximab) / Eli Lilly
New P2 trial, Surgery, Metastases:  COMBATAC: Combined Anticancer Treatment of Advanced Colon Cancer (clinicaltrials.gov) -  Feb 26, 2012
P2, N=60, Recruiting,  Sponsor: University of Regensburg

|||||||||| New P1/2 trial: Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation (clinicaltrials.gov) - Feb 25, 2012
P1/2, N=133, Completed, Sponsor: Arya, Vijaypal, M.D., P.C.

|||||||||| New P1 trial, Surgery, Metastases: Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases (clinicaltrials.gov) - Feb 6, 2012
P1, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center

||||||||||  Avastin (bevacizumab) / Roche
Trial termination, Metastases:  Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer (clinicaltrials.gov) -  Feb 1, 2012
P=N/A, N=2, Terminated,  Sponsor: Memorial Sloan-Kettering Cancer Center
N=93 --> 65 Completed --> Terminated; Lack of accrual

|||||||||| Trial termination: Pilot Study of Colon Cancer Screening Tests (clinicaltrials.gov) - Jan 30, 2012
P=N/A, N=198, Terminated, Sponsor: Hamilton Health Sciences Corporation
Completed --> Terminated; Lack of accrual Not yet recruiting --> Terminated; Lack of ongoing funding

|||||||||| Enrollment change: Pilot Study of Colon Cancer Screening Tests (clinicaltrials.gov) - Jan 30, 2012
P=N/A, N=198, Terminated, Sponsor: Hamilton Health Sciences Corporation
Not yet recruiting --> Terminated; Lack of ongoing funding N=600 --> 198

|||||||||| New P1/2 trial, Immunomodulating: A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer (clinicaltrials.gov) - Jan 25, 2012
P1/2, N=42, Recruiting, Sponsor: Holcombe, Randall F., M.D.

||||||||||  GI-6301 / BMS
New P1 trial:  Cancer Vaccine Targeting Brachyury Protein in Tumors (clinicaltrials.gov) -  Jan 25, 2012
P1, N=38, Recruiting,  Sponsor: GlobeImmune

|||||||||| Enrollment closed: Genetic Investigation of Solid Tumors Cohort (clinicaltrials.gov) - Jan 19, 2012
P=N/A, N=5000, Active, not recruiting, Sponsor: Scripps Translational Science Institute
N=600 --> 198 Recruiting --> Active, not recruiting

||||||||||  pidilizumab (CT-011) / CureTech
Trial withdrawal, Combination therapy, Metastases:  CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors (clinicaltrials.gov) -  Dec 29, 2011
P1, N=0, Withdrawn,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Withdrawn

||||||||||  pidilizumab (CT-011) / CureTech
Enrollment change, Combination therapy, Metastases:  CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors (clinicaltrials.gov) -  Dec 29, 2011
P1, N=0, Withdrawn,  Sponsor: National Cancer Institute (NCI)
Completed --> Withdrawn N=27 --> 0

|||||||||| Trial completion, Surgery: Laparoscopic Surgery Versus Robot Surgery for Right-side Colon Cancer: Short-term Outcome of a Randomised Clinical Trial (clinicaltrials.gov) - Dec 18, 2011
P2, N=80, Completed, Sponsor: Kyungpook National University
N=27 --> 0 Active, not recruiting --> Completed

|||||||||| Enrollment closed, Immunomodulating: Study of Effects of L-Arginine in Colitis and Colon Cancer (clinicaltrials.gov) - Dec 5, 2011
P=N/A, N=200, Active, not recruiting, Sponsor: Vanderbilt University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

|||||||||| Enrollment closed, HEOR: HOPE: Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (clinicaltrials.gov) - Nov 30, 2011
P=N/A, N=10, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

|||||||||| Clinical: Interventions to Improve Colon Cancer Screening in Poor Rural Iowa Counties (clinicaltrials.gov) - Nov 17, 2011
P=N/A, N=743, Active, not recruiting, Sponsor: University of Iowa

||||||||||  perifosine (D21266) / AEterna Zentaris
Trial completion, Metastases:  Study of Perifosine + Capecitabine for Colon Cancer Patients (clinicaltrials.gov) -  Oct 16, 2011
P1, N=10, Completed,  Sponsor: AEterna Zentaris
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Enrollment open: The Effects of Exercise Training on the Health-related Fitness of Colon Cancer Survivors (clinicaltrials.gov) - Sep 20, 2011
P2/3, N=52, Recruiting, Sponsor: AHS Cancer Control Alberta
Active, not recruiting --> Completed Not yet recruiting --> Recruiting